Baseline ECOG performance status 0 versus 1 as a modifier of treatment benefit from adding an immune checkpoint inhibitor to chemotherapy: A systematic review and meta-analysis
- DOI
- 10.1016/j.critrevonc.2026.105678
- Published
- 2026-12
- Container
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.critrevonc.2026.105678,
title = {Baseline ECOG performance status 0 versus 1 as a modifier of treatment benefit from adding an immune checkpoint inhibitor to chemotherapy: A systematic review and meta-analysis},
author = {Wafa Ali Asaad and Salah Ameen Abdu and Yueying Zhou and Guo Cheng and Li Ning},
year = {2026},
journal = {Critical Reviews in Oncology/Hematology},
doi = {10.1016/j.critrevonc.2026.105678},
url = {https://doi.org/10.1016/j.critrevonc.2026.105678}
}RIS
TY - JOUR TI - Baseline ECOG performance status 0 versus 1 as a modifier of treatment benefit from adding an immune checkpoint inhibitor to chemotherapy: A systematic review and meta-analysis AU - Wafa Ali Asaad AU - Salah Ameen Abdu AU - Yueying Zhou AU - Guo Cheng AU - Li Ning PY - 2026 JO - Critical Reviews in Oncology/Hematology DO - 10.1016/j.critrevonc.2026.105678 UR - https://doi.org/10.1016/j.critrevonc.2026.105678 ER -
APA
Asaad, W. A., Abdu, S. A., Zhou, Y., Cheng, G., & Ning, L. (2026). Baseline ECOG performance status 0 versus 1 as a modifier of treatment benefit from adding an immune checkpoint inhibitor to chemotherapy: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2026.105678
Source records
- crossref · retrieved 2026-11-04T14:06:50.745Z